## Ioannis Prassas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6179640/publications.pdf

Version: 2024-02-01

		1307594	1281871	
17	147	7	11	
papers	citations	h-index	g-index	
18	18	18	218	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	From the amyloid hypothesis to the autoimmune hypothesis of Alzheimer's disease. Diagnosis, 2022, 9, 280-281.	1.9	2
2	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. Clinical Chemistry and Laboratory Medicine, 2022, 60, 771-777.	2.3	11
3	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1116-1123.	2.3	3
4	Alzheimer Disease Pathogenesis: The Role of Autoimmunity. journal of applied laboratory medicine, The, 2021, 6, 756-764.	1.3	19
5	Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. Journal of Proteome Research, 2021, 20, 444-452.	3.7	11
6	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. JCO Precision Oncology, 2021, 5, 485-491.	3.0	5
7	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. F1000Research, 2021, 10, 509.	1.6	6
8	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
9	CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 107, 78-85.	3.1	5
10	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Research, 2020, 9, 337.	1.6	6
11	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Research, 2020, 9, 732.	1.6	2
12	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Research, 2020, 9, 732.	1.6	2
13	Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. Molecular Cancer Therapeutics, 2019, 18, 1844-1851.	4.1	13
14	A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. Clinical Proteomics, 2019, 16, 25.	2.1	15
15	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. Clinical Biochemistry, 2019, 66, 63-75.	1.9	3
16	Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. F1000Research, 2019, 8, 1900.	1.6	13
17	Towards personalized tumor markers. Npj Precision Oncology, 2017, 1, 17.	5.4	20